Content about Endocrine system

June 20, 2011

Last month, the Food and Drug Administration approved Tradjenta (linagliptin), an oral Type 2 diabetes drug made by German drug maker Boehringer Ingelheim and Indianapolis-based Eli Lilly. The drug belongs to the class known as dipeptidyl peptidase-4 inhibitors, which also includes Merck’s Januvia (sitagliptin). With diabetes affecting some 26 million Americans and growing rapidly, Drug Store News spoke with Wa’el Hashad, BI’s VP cardiovascular and metabolic disorders marketing, about what the approval of Tradjenta means for the diabetes market.


June 17, 2011

A popular Type 2 diabetes treatment may help Type 1 diabetics achieve control of their blood-glucose levels, according to a small, observational study conducted at the University of Buffalo.

BUFFALO, N.Y. — A popular Type 2 diabetes treatment may help Type 1 diabetics achieve control of their blood-glucose levels, according to a small, observational study conducted at the University of Buffalo.

June 13, 2011

Men with prostate cancer are at a higher risk of developing diabetes or diabetes risk factors if they receive a therapy designed to block the production of testosterone, a new study has suggested.

BOSTON — Men with prostate cancer are at a higher risk of developing diabetes or diabetes risk factors if they receive a therapy designed to block the production of testosterone, a new study has suggested.

June 9, 2011

Patients with Type 1 diabetes using an insulin product made by Eli Lilly can store it in their pumps for longer periods of time, while children using it have additional options, thanks to a labeling change approved Wednesday by the Food and Drug Administration.

INDIANAPOLIS — Patients with Type 1 diabetes using an insulin product made by Eli Lilly can store it in their pumps for longer periods of time, while children using it have additional options, thanks to a labeling change approved Wednesday by the Food and Drug Administration.

June 6, 2011

A new survey sponsored by drug maker Novo Nordisk, which polled Type 1 and Type 2 diabetes patients in the United States, United Kingdom, Germany and France, found that about 1-in-5 respondents regularly are unable to attend a full day of work due to disruption caused by episodes of dangerously low blood sugar, also known as hypoglycemic events.

COPENHAGEN, Denmark — A new survey sponsored by drug maker Novo Nordisk, which polled Type 1 and Type 2 diabetes patients in the United States, United Kingdom, Germany and France, found that about 1-in-5 respondents regularly are unable to attend a full day of work due to disruption caused by episodes of dangerously low blood sugar, also known as hypoglycemic events.

June 6, 2011

An investigational drug improved diabetes and lipid control in patients with partial lipodystrophy, according to a new study.

SAN DIEGO — An investigational drug improved diabetes and lipid control in patients with partial lipodystrophy, according to a new study.

Amylin Pharmaceuticals announced Saturday results of a study of metreleptin, an analog of the human hormone leptin. Results of the study were presented at the 93rd annual meeting and expo of the Endocrine Society in Boston.

June 2, 2011

A company that develops insulin-pump technology without tubing, such as the OmniPod insulin management system, has acquired a durable medical equipment distributor that specializes in direct-to-consumer sales of diabetes supplies.

BEDFORD, Mass. — A company that develops insulin-pump technology without tubing, such as the OmniPod insulin management system, has acquired a durable medical equipment distributor that specializes in direct-to-consumer sales of diabetes supplies.

June 1, 2011

The Food and Drug Administration is investigating a possible link between a class of birth control pills and a higher risk of blood clots in the women taking them, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration is investigating a possible link between a class of birth control pills and a higher risk of blood clots in the women taking them, the agency said.

May 31, 2011

New results from a late-stage clinical trial of a Sanofi drug for Type 2 diabetes indicated that the drug can reduce blood sugar in patients without increasing the risk of causing the blood sugar levels to dip too low, the French drug maker said Tuesday.

PARIS — New results from a late-stage clinical trial of a Sanofi drug for Type 2 diabetes indicated that the drug can reduce blood sugar in patients without increasing the risk of causing the blood sugar levels to dip too low, the French drug maker said Tuesday.

May 24, 2011

The American Diabetes Association announced that it will fund research that will examine the effectiveness of technology-based diabetes management devices.

ALEXANDRIA, Va. — The American Diabetes Association announced that it will fund research that will examine the effectiveness of technology-based diabetes management devices.

The studies, funded by the American Diabetes Association/Medtronic Technology in Diabetes Fellowship, will utilize Medtronic's CareLink database — a database of anonymous continuous glucose monitoring and insulin pump-derived data — to assess, evaluate and correlate the application of this and similar technologies used by patients with insulin-treated diabetes.

May 23, 2011

Church & Dwight in April launched the First Response Digital Ovulation Test, a new at-home ovulation test that can detect a woman’s personal luteinizing hormone surge — the hormonal indication of ovulation — based on her own individual hormone levels.

PRINCETON, N.J. — Church & Dwight in April launched the First Response Digital Ovulation Test, a new at-home ovulation test that can detect a woman’s personal luteinizing hormone surge — the hormonal indication of ovulation — based on her own individual hormone levels.

May 13, 2011

Diabetics that have trouble sleeping likely experience high insulin resistance and have a more difficult time controlling the disease, according to study findings published in the June issue of Diabetes Care.

NEW YORK — Diabetics that have trouble sleeping likely experience high insulin resistance and have a more difficult time controlling the disease, according to study findings published in the June issue of Diabetes Care.

Researchers said they monitored the sleep of 40 subjects with diabetes for a duration of six nights and also measured the subjects' insulin and glucose levels during clinical examinations. The subjects also reported if they generally suffered from symptoms of such sleep disturbances as insomnia, snoring or sleep apnea.

May 2, 2011

The Food and Drug Administration has approved a treatment made by Abbott for low testosterone in men, the drug maker said Friday.

ABBOTT PARK, Ill. — The Food and Drug Administration has approved a treatment made by Abbott for low testosterone in men, the drug maker said Friday.

Abbott announced the approval of AndroGel (testosterone gel) in the 1.62% strength, a clear, odorless topical gel for men with hypogonadism. The company already markets AndroGel in the 1% strength.

The new gel contains 40.5 mg of testosterone in two pump presses, while AndroGel 1% contains 50 mg in four pump presses, but the company said the two were not interchangeable.

April 29, 2011

According to a study by the Centers for Disease Control and Prevention released Wednesday, young people with diabetes face substantially higher medical costs than children and teens without the disease. The study found annual medical expenses for youth with diabetes were $9,061, compared with $1,468 for youth without the disease.

ATLANTA — According to a study by the Centers for Disease Control and Prevention released Wednesday, young people with diabetes face substantially higher medical costs than children and teens without the disease. The study found annual medical expenses for youth with diabetes were $9,061, compared with $1,468 for youth without the disease.

April 27, 2011

A drug designed to reduce the risk of premature birth among pregnant women has been submitted to the Food and Drug Administration for approval.

LIVINGSTON and PARSIPPANY, N.J. — A drug designed to reduce the risk of premature birth among pregnant women has been submitted to the Food and Drug Administration for approval.

April 27, 2011

Church & Dwight on Tuesday announced the launch of its First Response digital ovulation test, a new at-home ovulation test that can detect a woman's personal luteinizing hormone, or LH, surge — the hormonal indication of ovulation — based on her own individual hormone levels.

PRINCETON, N.J. — Church & Dwight on Tuesday announced the launch of its First Response digital ovulation test, a new at-home ovulation test that can detect a woman's personal luteinizing hormone, or LH, surge — the hormonal indication of ovulation — based on her own individual hormone levels.

April 26, 2011

The New Life Agency has added a prescription progesterone supplement and RESOLVE: the National Fertility Association to the Fertility Pharmacy Care Card.

RANCHO MIRAGE, Calif. — The New Life Agency has added a prescription progesterone supplement and RESOLVE: the National Fertility Association to the Fertility Pharmacy Care Card.

April 25, 2011

Health and wellness is a major focus for grocer Albertsons, and that also holds true for its youngest of customers. 


Enter Healthy Kidz Club. 


April 13, 2011

The Food and Drug Administration has accepted a regulatory approval application for a topical treatment for low testosterone made by Teva Pharmaceuticals and BioSante Pharmaceuticals, BioSante said Wednesday.

LINCOLNSHIRE, Ill. — The Food and Drug Administration has accepted a regulatory approval application for a topical treatment for low testosterone made by Teva Pharmaceuticals and BioSante Pharmaceuticals, BioSante said Wednesday.

The two companies said the FDA had accepted their application for Bio-T-Gel and expected to complete its review by mid-November.

April 5, 2011

Mylan subsidiary Bioniche Pharma has launched an injectable treatment for a rare metabolic disorder, Mylan said Tuesday.

PITTSBURGH — Mylan subsidiary Bioniche Pharma has launched an injectable treatment for a rare metabolic disorder, Mylan said Tuesday.

Mylan announced the launch of octreotide acetate injection in prefilled syringes, a generic version of Novartis’ Sandostatin, used to treat the disorder acromegaly and suppress or inhibit severe diarrhea related to certain tumors. Acromegaly results from excess growth hormone produced in the pituitary gland, causing fatigue and weakness, body odor and carpal tunnel syndrome.

April 4, 2011

A topical medication for treating low testosterone in men now is available, drug maker Eli Lilly said.

INDIANAPOLIS — A topical medication for treating low testosterone in men now is available, drug maker Eli Lilly said.

Lilly announced the availability of Axiron (testosterone), a topical solution designed for application under the arm.

The Food and Drug Administration approved Axiron in November, making it the only testosterone replacement therapy applied to the underarm.

March 31, 2011

A drug used to treat diabetes also may prevent it, according to a new study published in the journal Experimental Biology and Medicine.

CLEVELAND — A drug used to treat diabetes also may prevent it, according to a new study published in the journal Experimental Biology and Medicine.

Researchers at Case Western Reserve University took specially bred obese, prediabetic rats and gave them either Merck’s Januvia (sitagliptin), placebo or glyburide, an older diabetes drug. Both of the diabetes drugs lowered blood-glucose levels after the rats had eaten, but only Junuvia raised the total output of insulin by the pancreas while lowering levels of glucagon.

March 28, 2011

A study published online in the journal Diabetes Care, and slated for the April print issue, suggested that counting carbohydrates could lead to an improvement in quality of life and a reduction in body mass index and waist circumference in patients with Type 1 diabetes who receive continuous subcutaneous insulin infusions.

NEW YORK — A study published online in the journal Diabetes Care, and slated for the April print issue, suggested that counting carbohydrates could lead to an improvement in quality of life and a reduction in body mass index and waist circumference in patients with Type 1 diabetes who receive continuous subcutaneous insulin infusions.

March 24, 2011

Novo Nordisk said new data showed that its basal insulin analog is just as effective as human basal insulin in Type 1 diabetes patients ages 2 to 5 years.

COPENHAGEN — Novo Nordisk said new data showed that its basal insulin analog is just as effective as human basal insulin in Type 1 diabetes patients ages 2 to 5 years.

March 14, 2011

A drug maker focused on development and commercialization of diabetes treatments unveiled its accelerating clinical development plans of two drug candidates.

DANBURY, Conn. — A drug maker focused on development and commercialization of diabetes treatments unveiled its accelerating clinical development plans of two drug candidates.

Biodel said BIOD-105 and BIOD-107, known as ultra rapid-acting insulins, are designed to result in more rapid insulin action, compared with currently marketed mealtime insulin analogs.